Cellectar Biosciences, Inc. (CLRB)
NASDAQ: CLRB · Real-Time Price · USD
2.560
-0.050 (-1.92%)
At close: Apr 28, 2026, 4:00 PM EDT
2.670
+0.110 (4.30%)
After-hours: Apr 28, 2026, 4:57 PM EDT
Cellectar Biosciences Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Cellectar Biosciences stock has a target of 10, which predicts an increase of 290.62% from the current stock price of 2.56.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 10, 2026.
Analyst Ratings
According to 1 stock analyst, the rating for Cellectar Biosciences is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Hold → Strong Buy Upgrades $10 | Hold → Strong Buy | Upgrades | $10 | +290.62% | Mar 10, 2026 |
| Maxim Group | Maxim Group | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | May 14, 2025 |
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Dec 11, 2024 |
| Oppenheimer | Oppenheimer | Buy Maintains $420 → $360 | Buy | Maintains | $420 → $360 | +13,962.50% | Nov 19, 2024 |
| Oppenheimer | Oppenheimer | Buy Reiterates $420 | Buy | Reiterates | $420 | +16,306.25% | Oct 11, 2024 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
14.68M
EPS This Year
-3.75
from -8.35
EPS Next Year
-3.14
from -3.75
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 21.3M | ||||||
| Avg | n/a | 14.7M | ||||||
| Low | n/a | 8.3M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -2.90 | -1.59 | ||||||
| Avg | -3.75 | -3.14 | ||||||
| Low | -5.30 | -5.19 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.